Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps
December 03, 2009
Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps
A Santaris official also confirmed that an option giving GlaxoSmithKline an option to license the drug has expired, and that deals with other companies are underway.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.